TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Ascentage Pharma Group International
ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%

Ascentage Pharma presented promising Phase III study results for Olverembatinib in treating Philadelphia chromosome-positive acute lymphoblastic leukemia, showing a 66% minimal residual disease negativity rate and favorable safety profile.

Insights
TAK   neutral

Signed an exclusive option agreement for global rights to Olverembatinib, indicating potential strategic interest